Catholic University of Leuven

Catholic University of Leuven
Oude Markt 13, 3000 Leuven
Catholic University of Leuven  
Pharmacology - Feb 19
Chloroquine, an antimalarial medicine that has been on the international market since 1934, proves to be active against the novel SARS coronavirus type 2 (COVID-19). The antiviral activity of chloroquine was already discovered in 2004 by a team of virologists at KU Leuven.
Environment - Feb 13
Environment

An interdisciplinary team of bio-engineers and economists from KU Leuven has mapped out how wood could replace petroleum in the chemical industry.

Health - Jan 21

Researchers from KU Leuven and University Hospitals Leuven have managed to engineer living implants in the lab by mimicking how bone tissue is created in an embryo. The technology paves the way for bone-regenerating tissue implants created on an industrial scale using 3D bioprinting.

Life Sciences - Jan 14

Bioscience engineers from KU Leuven in Belgium have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. Unlike with antibiotics, there is no resistance to this strategy, because the non-resistant bacteria outnumber resistant ones.

Physics - Jan 4
Physics

Freestanding clusters of twenty gold atoms take the shape of a pyramid, researchers discovered. This is in contrast with most elements, which organize themselves by forming shells around one central atom.

Health - Jan 29

Biomedical scientists at KU Leuven have discovered that a defect in the ATP13A2 gene causes cell death by disrupting the cellular transport of polyamines. When this happens in the part of the brain that controls body movement, it can lead to Parkinson's disease.

Health - Jan 21

Oxytocin, often dubbed the 'love hormone', is known to promote social bonding. Researchers at KU Leuven have now discovered that administering oxytocin to adult men with autism makes them more open to close emotional bonds with others.

Health - Jan 9

An interdisciplinary team of scientists from KU Leuven, the University of Bremen, the Leibniz Institute of Materials Engineering, and the University of Ioannina has succeeded in killing tumour cells in mice using nano-sized copper compounds together with immunotherapy.

Pharmacology - Dec 16, 2019

Today, KU Leuven and VIB present a new venture, Augustine Therapeutics, with the mission to develop innovative therapeutics for patients suffering from Charcot-Marie-Tooth disease. Augustine raised a seed-round of 4.2 million euro with V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB.





This site uses cookies and analysis tools to improve the usability of the site. More information. |